Browse Trials
Find Breast Cancer Clinical Trials That Are Right For You
The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.
Use the search box and filters to find a trial that’s right for you.
Currently viewing trials
(Last updated: October 02, 2023)
Brain Mets
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Leptomeningeal Disease
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: ADC
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Activities
Complementary and Integrative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Healthy/High Risk
Imaging
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Support/Education
Surveys/Interviews/Registries
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
dMMR/MSI-H
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
NEAREST SITE: 1678 miles
University of Wisconsin-Site Number:8400004
Madison,WI
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT04659603
SAR408701 for CEACAM5-Positive Metastatic Breast Cancer
Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of SAR408701 in Patients With CEACAM5-positive Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Diphenhydramine, by mouth</li> <li class="seamTextUnorderedListItem">SAR408701, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SAR408701 is a type of drug called an antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">This means it uses an antibody that targets cancer cells to deliver a chemotherapy directly to these cells.</li> <li class="seamTextUnorderedListItem">SAR408701 targets a protein called CEACAM5 that is over-expressed on certain cancer cells.</li> <li class="seamTextUnorderedListItem">Diphenhydramine is a common antihistamine given before treatment.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04659603' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sanofi.com/en/about-us/our-stories/CEACAM5-and-Lung-Cancer' target='_blank'>Sanofi: CEACAM5 and Lung Cancer</a> </li></ul>
